Skip to main content
. 2011 Jan;13(1):72–80. doi: 10.1593/neo.101214

Figure 1.

Figure 1

C1311 and NSC exhibit similar, favorable in vitro activities, comparable to standard-of-care agents. (A) IC50 values for C1311 were determined by Spline regression for the BLA-40 cell line panel, plotted ranked ordered from left to right, then each corresponding cell line's expression of TOP2A and FLT3 expression (Affymetrix probes 201291_s_at and 206674_at, both log10 values for visualization in scale). (B) Scatter plot of NSC compound (ordinate) and C1311 (abscissa) IC50 values across the BLA-40 panel, nonparametric Spearman correlation, and P value. (C) Comparison of C1311 and standard-ofcare drugs by IC50 across the BLA-40 panel. IC50 values C1311, cisplatin, and gemcitabine were rank ordered for the 40 cell lines for each drug and plotted in ascending order on the log-scale y axis. The green, pink, and blue arrows indicate the percentage of the BLA-40 cell lines that exhibit IC50 values below the 1-µM range, demonstrating that C1311 exhibits similar activity to agents currently in clinical use.